MarginsXMarginsX
Home › Markets › Health Care › PRLD

Prelude Therapeutics Incorporated (PRLD)

PRLD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.41
-1.16% on the day
Market cap
$272.1M
Micro cap
Revenue · 2025
$12.1M
+73.4% on 2024
Net income · 2025
-$99.5M
-819.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/0001193125-26-099428-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPRLD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001678660
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$12.1M
Net income-$99.5M
Operating income-$104.6M
Net margin-819.6%
Operating margin-861.3%
Revenue growth+73.4%
Cash$35.3M
Total assets$141.3M
P/E (computed)Net income was not positive
P/S (computed)22.4×

Warning signs

Cash runway
9.5 months
$26.3M cash at June 30, 2026
Share count, 1 year
+41.0%
2025-08-11 to 2026-08-06 · +45.6% over 3 years
Going-concern doubt
No
10-Q filed August 11, 2026
Insider net buying, 12 months
$12.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-11
Cash and burn$26.3M cash; operating cash flow -$8.3M a quarter.Report 2026-06-30
Shares outstanding79,803,485 (2026-08-06); 56,600,345 a year earlier; 54,808,715 three years earlier.Cover page 2026-08-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-04-21
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $12.5M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$5.7M-$13.9M-$15.6M$26.3MNo debt tags$22.4M10-Q 2026-08-11
Q1 2026
2026-03-31
$4.6M-$10.4M-$21.7M$21.8MNo debt tags$16.7M10-Q 2026-05-12
Q4 2025
2025-12-31
$5.6M-$16.5M$23.1M$35.3MNo debt tags$12.1M10-K 2026-03-10
Q3 2025
2025-09-30
$6.5M-$19.7M-$19.1M$47.5MNo debt tags$10.5M10-Q 2025-11-12
Q2 2025
2025-06-30
$0-$31.2M-$26.1M$25.8MNo debt tags$7.0M10-Q 2026-08-11
Q1 2025
2025-03-31
$0-$32.1M-$34.2M$40.3MNo debt tagsNeeds four quarters10-Q 2026-05-12
Q4 2024
2024-12-31
$4.0M-$28.7M-$20.7M$12.5MNo debt tags$7.0M10-K 2026-03-10
Q3 2024
2024-09-30
$3.0M-$32.3M-$27.3M$11.1MNo debt tagsNeeds four quarters10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-04-21
Latest annual report10-K2026-03-10
Latest quarterly / interim10-Q2026-08-11
Latest current report8-K2026-09-10
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 389 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.2%
1 month-3.1%
3 months-35.6%
Year to date+19.0%
1 year+128.5%
From 52-week high-48.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
INOInovio Pharmaceuticals Inc.$1.40-2.10%$262.2M
TTRXTurn Therapeutics Inc.$8.55-8.51%$261.4M
FULCFulcrum Therapeutics Inc.$3.71-1.59%$283.4M
EVMNEvommune Inc.$7.10-6.95%$293.6M
QTTBQ32 Bio Inc.$8.29-4.82%$248.1M
EBSEmergent BioSolutions Inc.$5.81+0.35%$298.7M
ALTAltimmune Inc.$1.56-5.17%$303.6M
LFCRLifecore Biomedical Inc.$6.42-0.08%$243.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier